Is Crispr Therapeutics (CRSP) The Best Gene-Editing Stock to Buy Now? [Yahoo! Finance]
CRISPR Therapeutics (CRSP) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $110.00 price target on the stock, up from $105.00.
A Look At CRISPR Therapeutics (CRSP) Valuation After Upsized US$550 Million Convertible Note Offering [Yahoo! Finance]
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know [Yahoo! Finance]
CRISPR Therapeutics (CRSP) Reports $116M FY25 Revenue Driven by CASGEVY Growth [Yahoo! Finance]